Objective: The purpose of this study was to determine whether prostatic aspirate culture is a superior method to detect infection compared to culture of urine collected by cystocentesis in dogs with prostatic neoplasia.
Materials And Methods: A prospective study was conducted and dogs with suspected or confirmed prostatic neoplasia were enrolled. Urinalysis was done and culture and antimicrobial susceptibility testing was performed on paired urine and prostatic aspirate samples collected at a single timepoint.
Results: Ten dogs with prostatic neoplasia were enrolled. All dogs had one or more clinical sign consistent with lower urinary tract disease. One dog (10%) had a positive urine culture, but negative prostatic aspirate culture, one dog (10%) had a positive prostatic aspirate culture, but negative urine culture, and one dog (10%) had both positive urine and prostatic aspirate cultures. Using prostatic aspirate culture as the reference standard, urine culture had a sensitivity for detecting infection of 87.5% (95% confidence interval 52.9 to 99.4) and specificity of 50% (92.6 to 97.4) in this population of dogs.
Clinical Significance: Positive cultures were uncommon with both culture collection methods. Study results did not identify prostatic aspirate culture to be a more sensitive method of detecting prostatic infection than urine culture collected by cystocentesis in these dogs with prostatic neoplasia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jsap.13556 | DOI Listing |
Cureus
December 2024
Department of Urology, Takikawa Municipal Hospital, Takikawa, JPN.
We report here a rare case of a concurrent occurrence of abscesses caused by in the prostate, seminal vesicles, and epididymis. A 71-year-old male presented to our hospital with urinary retention, and an indwelling urethral catheter was inserted. He remained afebrile until a revisit one month later when he developed a fever and left scrotal swelling.
View Article and Find Full Text PDFJ Assoc Genet Technol
January 2024
The International Circle of Genetics Studies, Stony Brook Chapter, NY.
We report a 76-year-old male patient with myelodysplastic syndrome (MDS) with a t(9;22) and deletion 20q only by FISH. Past medical history is significant for prostate cancer status post radiation therapy and a 28-pack-year smoking history. In 2016, the patient developed a DVT and incidentally was found to have a BCR::ABL1 (p210) by PCR analysis (level of 0.
View Article and Find Full Text PDFOncogene
November 2024
Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, USA.
Clin Genitourin Cancer
February 2025
Department of Oncology, Athens Medical Center, Marousi, Greece.
Background: Cabazitaxel is an effective treatment in metastatic castration-resistant prostate cancer (mCRPC) patients previously exposed to docetaxel and novel hormonal treatments. Understanding the molecular biology of mCRPC disease and taking into account the several approved treatment options, biomarkers are needed to guide decision making including cabazitaxel treatment.
Methods: Cababone was a phase II translational study that attempted to identify predictors of cabazitaxel efficacy.
Semin Oncol Nurs
December 2024
Lead Clinical Nurse Specialist Gestational Trophoblastic Disease and Rare Gynae Cancers, Imperial College.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!